Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs, CasZyme Collaborate to Identify, Commercialize CRISPR-Cas Nucleases

NEW YORK (GenomeWeb) – New England Biolabs and startup company CasZyme announced today that they have formed a multi-year collaboration to identify and commercialize CRISPR-Cas nucleases.

Under the terms of the agreement, the two companies will work to characterize new Cas nucleases using their expertise in enzymology, and NEB will then manufacture and commercially distribute the nucleases globally.

"The scientific founders of CasZyme are pioneers in CRISPR-Cas research, with a significant history of advancing our understanding of key enzymes involved in nucleic acid recognition in the context of bacterial immune systems," Ted Davis, NEB's executive director of applications and product development, said in a statement. "We are excited to undertake this joint endeavor that we believe will advance CRISPR-Cas science and enable new applications of Cas9 enzymes in vitro and in vivo."

CasZyme, which is based in Lithuania, is developing and characterizing new tools to support CRISPR-Cas research. One of its founders is Vilnius University Professor Virginijus Šikšnys, who demonstrated in 2012 that CRISPR-Cas9 can be used to engineer precise double-strand breaks in DNA.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.